ANRO - candlestick chart analysis of Alto Neuroscience Inc.

Popular stocks today

AAPL AMD ASTS CMG DVN GNL IWM LFCR MSOS NVDA PGX PLTR SPY STNG TLT TSLA URA VGSH VZ WULF

Membership
- Log In
- Log Out
- Sign Up
- About HotCandlestick
- Benefits
- Help
Candlestick Charts
Chart Education
Trading Tools
Opportunities
External Links

Official PayPal Seal

As Seen In...

The Complete Guide to Using Candlestick Charting: How to Earn High Rates of Return safely

End of day quotes updated Wed Mar 18 15:45 CST
🏠

⎙

🔍

◄ Daily Pattern ► ◄ Weekly Pattern ► ◄ Monthly Pattern ► ◄ Quarterly Pattern ►
Bullish Doji Star Bullish Three Inside Up none none
29-Jan-2026 24-Oct-2025 unknown unknown
-1.2 strength -421.7 strength

ANRO	SPY
0.7 1.2 14.4 26.5 26.5	-1.4 -0.1 -3.6 -3.0 -3.0
% Price Gain WTD Performance (%) MTD Performance (%) QTD Performance (%) YTD Performance (%)
SPY tracks S&P 500 index.

ANRO News
16-Mar-2026 5:03 AM CST - Business Wire Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights $anro #cns--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full year ended December 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. Alto enters 2026 with a very strong clinical and financial foundation, said Amit Etkin, M.D., Ph.D., founder and
13-Mar-2026 7:03 AM CST - Business Wire Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum $anro #cns--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Companys management team will participate in a virtual fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 12:00pm ET. The presentation will be accessible via a live webcast on the Events and Presentations page in the Investo
23-Feb-2026 7:33 AM CST - Business Wire Alto Neuroscience Announces Participation in Upcoming Investor Conferences $anro #cns--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Companys management team will participate in the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference, March 2-5, 2026 Format: Fireside chat and one-on-one meetings Presentation Date & Time: March 3, 2026, 1:50
12-Nov-2025 6:57 AM CST - Business Wire Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights $anro #cns--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended September 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. These past months marked a period of significant strategic execution and validation for Alto. The successful outcome
28-Oct-2025 6:34 AM CST - Business Wire Alto Neuroscience to Participate in Upcoming Investor Conferences $anro #cns--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Companys management team will present at the following upcoming investor conferences: Stifel 2025 Healthcare Conference, November 11-13, 2025 Format: Fireside chat and one-on-one meetings Presentation Date & Time: Wednesday, November 12 at 1
18-Aug-2025 7:03 AM CST - Business Wire Alto Neuroscience to Participate in Upcoming Investor Conferences $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events: H.C. Wainwright Biotech Breakthroughs: Precision Neuropsychiatry Panel Format: Panel discussion Presentation Date & Time: Thursday, August 21, 202
13-Aug-2025 3:10 PM CST - Business Wire Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. We have had an exciting past few months marked by a promising addition to our pipeline with ALTO-207 and encouraging clin
30-Jun-2025 7:03 AM CST - Business Wire Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today highlighted The Lancet Psychiatry publication of data from the PAX-D study evaluating pramipexole in patients with treatment-resistant depression (TRD). The study was conducted by the University of Oxford and was funded by the UK governments National Institute for Health and
3-Jun-2025 5:03 AM CST - Business Wire Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that it entered into an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of potentially best-in-class dopamine agonist drug combinations, including ALTO-207, formerly known as CTC-501, for treatment resistant depression (TRD), generally

Disclaimer Privacy Contact

Copyright © 2001-2026, All rights reserved.
HotCandlestick.com, LLC

ANRO News
16-Mar-2026 5:03 AM CST - Business Wire Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights $anro #cns--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full year ended December 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. Alto enters 2026 with a very strong clinical and financial foundation, said Amit Etkin, M.D., Ph.D., founder and
13-Mar-2026 7:03 AM CST - Business Wire Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum $anro #cns--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Companys management team will participate in a virtual fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 12:00pm ET. The presentation will be accessible via a live webcast on the Events and Presentations page in the Investo
23-Feb-2026 7:33 AM CST - Business Wire Alto Neuroscience Announces Participation in Upcoming Investor Conferences $anro #cns--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Companys management team will participate in the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference, March 2-5, 2026 Format: Fireside chat and one-on-one meetings Presentation Date & Time: March 3, 2026, 1:50
12-Nov-2025 6:57 AM CST - Business Wire Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights $anro #cns--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended September 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. These past months marked a period of significant strategic execution and validation for Alto. The successful outcome
28-Oct-2025 6:34 AM CST - Business Wire Alto Neuroscience to Participate in Upcoming Investor Conferences $anro #cns--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Companys management team will present at the following upcoming investor conferences: Stifel 2025 Healthcare Conference, November 11-13, 2025 Format: Fireside chat and one-on-one meetings Presentation Date & Time: Wednesday, November 12 at 1
18-Aug-2025 7:03 AM CST - Business Wire Alto Neuroscience to Participate in Upcoming Investor Conferences $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events: H.C. Wainwright Biotech Breakthroughs: Precision Neuropsychiatry Panel Format: Panel discussion Presentation Date & Time: Thursday, August 21, 202
13-Aug-2025 3:10 PM CST - Business Wire Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. We have had an exciting past few months marked by a promising addition to our pipeline with ALTO-207 and encouraging clin
30-Jun-2025 7:03 AM CST - Business Wire Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today highlighted The Lancet Psychiatry publication of data from the PAX-D study evaluating pramipexole in patients with treatment-resistant depression (TRD). The study was conducted by the University of Oxford and was funded by the UK governments National Institute for Health and
3-Jun-2025 5:03 AM CST - Business Wire Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that it entered into an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of potentially best-in-class dopamine agonist drug combinations, including ALTO-207, formerly known as CTC-501, for treatment resistant depression (TRD), generally